Phase I study of humanized monoclonal antibody AVE1642 directed against the type 1 insulin-like growth factor receptor (IGF-1R), administered in combination with anticancer therapies to patients with advanced solid tumors.
BACKGROUND: Type 1 insulin-like growth factor receptor (IGF-1R) mediates resistance to chemotherapy and targeted agents. This study assessed the safety, pharmacokinetics (PK), and tolerability of humanized IGF-1R antibody AVE1642 with other cancer treatments. PATIENTS: Patients with advanced solid t...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
2013
|
| _version_ | 1826278678944808960 |
|---|---|
| author | Macaulay, V Middleton, M Protheroe, A Tolcher, A Dieras, V Sessa, C Bahleda, R Blay, J LoRusso, P Mery-Mignard, D Soria, J |
| author_facet | Macaulay, V Middleton, M Protheroe, A Tolcher, A Dieras, V Sessa, C Bahleda, R Blay, J LoRusso, P Mery-Mignard, D Soria, J |
| author_sort | Macaulay, V |
| collection | OXFORD |
| description | BACKGROUND: Type 1 insulin-like growth factor receptor (IGF-1R) mediates resistance to chemotherapy and targeted agents. This study assessed the safety, pharmacokinetics (PK), and tolerability of humanized IGF-1R antibody AVE1642 with other cancer treatments. PATIENTS: Patients with advanced solid tumors received three weekly AVE1642 dosed at 6 mg/kg, chosen following previous study, with 75 (cohort A) or 100 mg/m(2) (B) docetaxel, 1250 mg/m(2) gemcitabine/100 mg erlotinib (C1), or 60 mg/m(2) doxorubicin (D1). Blood samples were assayed for PK, IGFs, and IGF-BP3. RESULTS: Fifty-eight patients received 317 AVE1642 infusions. The commonest adverse events were diarrhea (37/58 patients), asthenia (34/58), nausea (30/58), and stomatitis (21/58). Dose-limiting toxic effects in cohorts C1 (diarrhea) and D1 (neutropenia) prompted addition of cohorts C2 (1000 mg/m(2) gemcitabine/75 mg erlotinib) and D2 (50 mg/m(2) doxorubicin). Grade 3-4 hyperglycemia (three cases) accompanied steroid premedication for docetaxel administration. No PK interactions were detected. There were three partial responses in cohorts B (melanoma) and C (leiomyosarcoma, two cases) and 22 stabilizations ≥12 weeks, giving a control rate of 25/57 (44%). On treatment IGF-II rose by 68 ± 25 ng/ml in patients discontinuing treatment <12 weeks, and fell by 55.5 ± 21 ng/ml with disease control (P < 0.001). CONCLUSION: AVE1642 was tolerable with 75-100 mg/m(2) docetaxel and 1000 mg/m(2) gemcitabine/75 mg erlotinib, achieving durable disease control in 44%, with an association between IGF-II and response. |
| first_indexed | 2024-03-06T23:47:32Z |
| format | Journal article |
| id | oxford-uuid:7176a965-10ea-4d93-b112-54f1fc81405f |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T23:47:32Z |
| publishDate | 2013 |
| record_format | dspace |
| spelling | oxford-uuid:7176a965-10ea-4d93-b112-54f1fc81405f2022-03-26T19:43:46ZPhase I study of humanized monoclonal antibody AVE1642 directed against the type 1 insulin-like growth factor receptor (IGF-1R), administered in combination with anticancer therapies to patients with advanced solid tumors.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:7176a965-10ea-4d93-b112-54f1fc81405fEnglishSymplectic Elements at Oxford2013Macaulay, VMiddleton, MProtheroe, ATolcher, ADieras, VSessa, CBahleda, RBlay, JLoRusso, PMery-Mignard, DSoria, JBACKGROUND: Type 1 insulin-like growth factor receptor (IGF-1R) mediates resistance to chemotherapy and targeted agents. This study assessed the safety, pharmacokinetics (PK), and tolerability of humanized IGF-1R antibody AVE1642 with other cancer treatments. PATIENTS: Patients with advanced solid tumors received three weekly AVE1642 dosed at 6 mg/kg, chosen following previous study, with 75 (cohort A) or 100 mg/m(2) (B) docetaxel, 1250 mg/m(2) gemcitabine/100 mg erlotinib (C1), or 60 mg/m(2) doxorubicin (D1). Blood samples were assayed for PK, IGFs, and IGF-BP3. RESULTS: Fifty-eight patients received 317 AVE1642 infusions. The commonest adverse events were diarrhea (37/58 patients), asthenia (34/58), nausea (30/58), and stomatitis (21/58). Dose-limiting toxic effects in cohorts C1 (diarrhea) and D1 (neutropenia) prompted addition of cohorts C2 (1000 mg/m(2) gemcitabine/75 mg erlotinib) and D2 (50 mg/m(2) doxorubicin). Grade 3-4 hyperglycemia (three cases) accompanied steroid premedication for docetaxel administration. No PK interactions were detected. There were three partial responses in cohorts B (melanoma) and C (leiomyosarcoma, two cases) and 22 stabilizations ≥12 weeks, giving a control rate of 25/57 (44%). On treatment IGF-II rose by 68 ± 25 ng/ml in patients discontinuing treatment <12 weeks, and fell by 55.5 ± 21 ng/ml with disease control (P < 0.001). CONCLUSION: AVE1642 was tolerable with 75-100 mg/m(2) docetaxel and 1000 mg/m(2) gemcitabine/75 mg erlotinib, achieving durable disease control in 44%, with an association between IGF-II and response. |
| spellingShingle | Macaulay, V Middleton, M Protheroe, A Tolcher, A Dieras, V Sessa, C Bahleda, R Blay, J LoRusso, P Mery-Mignard, D Soria, J Phase I study of humanized monoclonal antibody AVE1642 directed against the type 1 insulin-like growth factor receptor (IGF-1R), administered in combination with anticancer therapies to patients with advanced solid tumors. |
| title | Phase I study of humanized monoclonal antibody AVE1642 directed against the type 1 insulin-like growth factor receptor (IGF-1R), administered in combination with anticancer therapies to patients with advanced solid tumors. |
| title_full | Phase I study of humanized monoclonal antibody AVE1642 directed against the type 1 insulin-like growth factor receptor (IGF-1R), administered in combination with anticancer therapies to patients with advanced solid tumors. |
| title_fullStr | Phase I study of humanized monoclonal antibody AVE1642 directed against the type 1 insulin-like growth factor receptor (IGF-1R), administered in combination with anticancer therapies to patients with advanced solid tumors. |
| title_full_unstemmed | Phase I study of humanized monoclonal antibody AVE1642 directed against the type 1 insulin-like growth factor receptor (IGF-1R), administered in combination with anticancer therapies to patients with advanced solid tumors. |
| title_short | Phase I study of humanized monoclonal antibody AVE1642 directed against the type 1 insulin-like growth factor receptor (IGF-1R), administered in combination with anticancer therapies to patients with advanced solid tumors. |
| title_sort | phase i study of humanized monoclonal antibody ave1642 directed against the type 1 insulin like growth factor receptor igf 1r administered in combination with anticancer therapies to patients with advanced solid tumors |
| work_keys_str_mv | AT macaulayv phaseistudyofhumanizedmonoclonalantibodyave1642directedagainstthetype1insulinlikegrowthfactorreceptorigf1radministeredincombinationwithanticancertherapiestopatientswithadvancedsolidtumors AT middletonm phaseistudyofhumanizedmonoclonalantibodyave1642directedagainstthetype1insulinlikegrowthfactorreceptorigf1radministeredincombinationwithanticancertherapiestopatientswithadvancedsolidtumors AT protheroea phaseistudyofhumanizedmonoclonalantibodyave1642directedagainstthetype1insulinlikegrowthfactorreceptorigf1radministeredincombinationwithanticancertherapiestopatientswithadvancedsolidtumors AT tolchera phaseistudyofhumanizedmonoclonalantibodyave1642directedagainstthetype1insulinlikegrowthfactorreceptorigf1radministeredincombinationwithanticancertherapiestopatientswithadvancedsolidtumors AT dierasv phaseistudyofhumanizedmonoclonalantibodyave1642directedagainstthetype1insulinlikegrowthfactorreceptorigf1radministeredincombinationwithanticancertherapiestopatientswithadvancedsolidtumors AT sessac phaseistudyofhumanizedmonoclonalantibodyave1642directedagainstthetype1insulinlikegrowthfactorreceptorigf1radministeredincombinationwithanticancertherapiestopatientswithadvancedsolidtumors AT bahledar phaseistudyofhumanizedmonoclonalantibodyave1642directedagainstthetype1insulinlikegrowthfactorreceptorigf1radministeredincombinationwithanticancertherapiestopatientswithadvancedsolidtumors AT blayj phaseistudyofhumanizedmonoclonalantibodyave1642directedagainstthetype1insulinlikegrowthfactorreceptorigf1radministeredincombinationwithanticancertherapiestopatientswithadvancedsolidtumors AT lorussop phaseistudyofhumanizedmonoclonalantibodyave1642directedagainstthetype1insulinlikegrowthfactorreceptorigf1radministeredincombinationwithanticancertherapiestopatientswithadvancedsolidtumors AT merymignardd phaseistudyofhumanizedmonoclonalantibodyave1642directedagainstthetype1insulinlikegrowthfactorreceptorigf1radministeredincombinationwithanticancertherapiestopatientswithadvancedsolidtumors AT soriaj phaseistudyofhumanizedmonoclonalantibodyave1642directedagainstthetype1insulinlikegrowthfactorreceptorigf1radministeredincombinationwithanticancertherapiestopatientswithadvancedsolidtumors |